Abstracts tagged "Outcome measures"

Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 0761 • ACR Convergence 2024
An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis
Ioannis Koulas¹, Nikolaos Tsaftaridis², Ivana Ilic³, Jack Jnani⁴, Alex Spyropoulos¹ and Lara El Khoury⁵, ¹Feinstein Institutes for Medical Research/Northwell Health, Manhasset, ²Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, ³Northwell, Brooklyn, NY, ⁴Department of Medicine/Northwell Health, Manhasset, ⁵Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
Abstract Number: 1067 • ACR Convergence 2024
Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Ali Nasir¹ and Nasir Khan², ¹Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, ²Trinity Health Grand Rapids, Grand Rapids, MI
Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
Abstract Number: 1437 • ACR Convergence 2024
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Sze-Lok Lau¹, Huan Meng², Isaac Cheng¹, Bryan PY Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), ³The Chinese University of Hong Kong, New Territories, Hong Kong
Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
Abstract Number: 1670 • ACR Convergence 2024
Predictors of 6-Minute Walk Test Performance in Adults with Arthritis
Kailyn Horn, Scott Jamieson, Katherine Devivo, Sara Wilcox, Yesil Kim, Chih-Hsiang Yang and Christine Pellegrini, University of South Carolina, Columbia, SC
Background/Purpose: The 6-Minute Walk Test (6MWT) is a measure commonly used by clinicians to assess functional capacity and rehabilitation progress. While predictors of 6MWT performance…
Abstract Number: 2173 • ACR Convergence 2024
Hope and Health in Adolescents with Chronic Musculoskeletal Pain
Irene Chern¹, Mackenzie McGill², Nellie P Butler² and Sabrina Gmuca², ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Hope, the capability to derive pathways to desired goals and motivate oneself via agency thinking plays a protective role in pediatric health contributing to…
Abstract Number: 2392 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Güllü Sandal Uzun¹ and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM) are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
Abstract Number: 0242 • ACR Convergence 2024
Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents
Cassandra Calabrese¹, Xiaofang wang², Abhijit Duggal², Gretchen Sacha², Shuaiqi Huang² and Leonard Calabrese², ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients constitute a high-risk group for severe COVID-19 outcomes and those on B cell depleting therapy (BCTD) are among the most vulnerable. Previous…
Abstract Number: 0403 • ACR Convergence 2024
Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
Melissa Oliver¹, susan Thornhill², Beverley Shea³, Jonathan Akikusa², Christian Hedrich⁴, Philip Mease⁵ and Yongdong (Dan) Zhao⁶, and OMERACT CNO & SAPHO Working Group, ¹Indiana University, Indianapolis, IN, ²Royal Children's Hospital, Parkville, Victoria, Australia, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶University of Washington, Redmond, WA
Background/Purpose: Disease outcome measures for chronic nonbacterial osteomyelitis (CNO) & Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) have been proposed and reported but have lacked…
Abstract Number: 0625 • ACR Convergence 2024
Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza
Asim Khanfar¹, Shiamak Cooper², Ali Mohamed³, Tanvi Borse⁴ and Sarah Nalwalla⁵, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY, ³Internal Medicine Resident, Rochester General Hospital, Rochester, NY, ⁴Parkview Health, Fort Wayne, IN, ⁵Seth GSMC and KEM Hospital, Mumbai, India
Background/Purpose: SLE is a chronic autoinflammatory condition affecting multiple organ systems. Patients with SLE are at a higher risk for infection compared to the general…
Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Suzanne D. Khalili¹, Daniel Aletaha³ and Josef Smolen⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…
Abstract Number: 1118 • ACR Convergence 2024
The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³ and Omer Pamuk⁴, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Timothy Brandon¹, Rui Xiao², Cassandra Muir¹, Matthew Stoll³, Daniel Lovell⁴, Edward Oberle⁵, Nancy Chauvin⁶, Michael Francavilla⁷, Walter Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, ⁷Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
Abstract Number: 1684 • ACR Convergence 2024
Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Eduardo Gomez¹, Daniel Goldman², Merlin Paz³, Michelle Petri² and Felipe Andrade⁴, ¹The Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins Medicine, Baltimore, MD, ⁴The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…
Abstract Number: 2182 • ACR Convergence 2024
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Lauren Arrigoni², Kevin Rubenstein³, Max Wolff⁴, Mallory Barrix², C. Jason Liang⁵, James Bost⁶, Meghan Delaney⁷, Luigi Notarangelo⁸, Karyl Barron⁹ and Roberta DeBiasi¹⁰, and PECOS Study Team, ¹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, ²Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, ³Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁵Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, ⁶Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, ⁷Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, ⁸Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, ⁹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ¹⁰Children's National Hospital and Research Institute, Washington, DC
Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…

« Previous Page
1
…
7
8
9
10
11
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].